Leukemia
Conditions
Keywords
childhood acute myeloid leukemia/other myeloid malignancies
Brief summary
RATIONALE: Studying the effects of obatoclax mesylate in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of obatoclax mesylate on cancer cells. It may also help doctors identify biomarkers related to cancer. PURPOSE: This research study is studying obatoclax mesylate in samples from young patients with acute myeloid leukemia.
Detailed description
OBJECTIVES: * Determine comprehensive gene and protein expression profiles of in vitro sensitivity and resistance to obatoclax mesylate in multiple-lineage leukemia (MLL)-rearranged cell lines and primary infant acute myeloid leukemia (AML) samples. * Define optimum in vitro combinations of obatoclax mesylate targeting pro-survival BCL-2 family proteins with cytotoxic drugs in MLL-rearranged leukemia cell lines and primary infant AML samples. * Identify synergistic combinations based on a pharmacodynamic modeling and simulation construct. * Determine whether combinations of obatoclax mesylate targeting pro-survival BCL-2 family proteins with cytotoxic drugs improves survival in a xenograft model of MLL-rearranged infant AML. OUTLINE: This is a multicenter study. Obatoclax mesylate activity is assessed via the MTT assay. A priori features of acute myeloid leukemia (AML) blasts relating to the apoptosis and ATG cell death pathways and their execution are characterized using microarray analysis and quantitative real-time (Q-RT) PCR. Gene and protein expression is described and quantified using Q-RT PCR and western blot analysis at specific time points after obatoclax mesylate exposure to identify pharmacodynamic biomarkers of activity and characterize the cell death mechanism in multiple-lineage leukemia (MLL)+ AML. The MTT assay is performed using obatoclax mesylate-cytotoxic chemotherapy combinations to determine synergy focusing on common cytotoxic drugs employed in AML treatment regimens. Obatoclax mesylate efficacy is tested in a therapeutic NOG xenograft model of primary MLL+ infant AML.
Interventions
GENETICgene expression analysis
GENETICmicroarray analysis
GENETICprotein expression analysis
GENETICreverse transcriptase-polymerase chain reaction
GENETICwestern blotting
OTHERlaboratory biomarker analysis
OTHERpharmacological study
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 2 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of acute myeloid leukemia (AML) * Cryopreserved samples from infants with AML available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease progression in a xenograft model of MLL-rearranged infant AML | — |
| Obatoclax mesylate activity | — |
| Optimum in vitro combinations of obatoclax mesylate | — |
| Pharmacodynamic (PD) biomarkers of activity | — |
| Cell death mechanism in multiple-lineage leukemia (MLL) acute myeloid leukemia (AML) | — |
Secondary
| Measure | Time frame |
|---|---|
| Peripheral blast count reduction | — |
| Apoptosis and/or ATG induction | — |
| Modulation of relevant PD biomarkers | — |
| Physical assessment (in xenograft model) | — |
Outcome results
None listed